Abstract
The smallpox vaccine, which is based on vaccinia virus, has been effective in preventing this disease. Since the World Health Organization declared the eradication of smallpox in 1980, there has been no concern about the natural occurrence of smallpox, so vaccinations of the general population is not currently being conducted. However, as the variola virus is a pathogen that is possibly to be used in bioterrorism and is vaccinated against bioterrorism response personnel and people who may be exposed to the virus. These smallpox vaccines can cause local and minor adverse reactions, and in the case of the first and second generation smallpox vaccines, serious life-threatening complications may occur. Accordingly, vaccinia immune globulin (VIG) is used as a treatment for abnormal reactions caused by vaccination of the smallpox. However, since “VIG” is produced using the sera of people vaccinated against smallpox, the effectiveness and production between lots are variable, and demand may exceed supply. To compensate for these shortcomings, research and development of a smallpox vaccine side effect treatment that can be produced in various ways, based on human monoclonal antibodies with neutrality against the vaccinia virus and with standard effectiveness is underway.